First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer

阿替唑单抗 医学 紫杉醇 肿瘤科 人口 内科学 成本效益 乳腺癌 癌症 彭布罗利珠单抗 免疫疗法 环境卫生 风险分析(工程)
作者
Xiuhua Weng,Xiaoting Huang,Hongchao Li,Lin Shen,Xin Rao,Xianzhong Guo,Pinfang Huang
出处
期刊:American Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (5): 340-348 被引量:29
标识
DOI:10.1097/coc.0000000000000671
摘要

Objective: The authors conducted a cost-effectiveness analysis incorporating recent phase III clinical trial (IMpassion130) data to evaluate the cost-effectiveness of atezolizumab in combination with nab-paclitaxel (AnP) against nab-paclitaxel alone as the first-line treatment for advanced triple-negative breast cancer in developed and developing countries. Materials and Methods: A decision-analytic Markov model was developed using IMpassion130 data to evaluate the cost-effectiveness of AnP over a lifetime from the US health care payer and Chinese health care system perspective. Model inputs were derived from IMpassion130 and published literature. The primary outcomes of the model were quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs). Uncertainty was addressed using univariate and probabilistic sensitivity analyses. Results: For the intention-to-treat (ITT) population, the projected mean outcome was better with AnP (1.41 QALYs) than with nab-paclitaxel alone (0.99 QALYs). Similar results were obtained for the programmed death ligand 1 (PD-L1)-positive population, with the obtained mean outcomes of 1.66 and 0.88 QALYs, respectively. For the Unites States, the ICER values comparing AnP with nab-paclitaxel were US$331,996.89 and US$229,359.88 per QALY gained for the ITT and PD-L1-positive populations, respectively. For China, the ICER values were US$106,339.26 and US$72,971.88 per QALY gained for the ITT and PD-L1-positive populations, respectively. The univariate sensitivity analysis indicated that the price of atezolizumab was the most influential factor in our study. AnP had 0% cost-effectiveness at the willingness-to-pay thresholds of US$150,000/QALY in the United States and US$29,383/QALY in China. Conclusion: AnP is not a cost-effective choice as the first-line treatment for advanced triple-negative breast cancer in the United States and China.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
可爱的函函应助过氧化氢采纳,获得30
2秒前
2秒前
锦鲤完成签到 ,获得积分10
3秒前
任性的白玉完成签到 ,获得积分10
3秒前
youwenjing11发布了新的文献求助10
4秒前
山谷完成签到 ,获得积分10
4秒前
钱宇成发布了新的文献求助10
5秒前
科研通AI2S应助感动黄豆采纳,获得10
9秒前
13秒前
14秒前
17秒前
Fengliguantou发布了新的文献求助10
17秒前
猪猪hero发布了新的文献求助10
19秒前
Winner发布了新的文献求助10
21秒前
隐形曼青应助科研通管家采纳,获得10
21秒前
领导范儿应助科研通管家采纳,获得10
21秒前
Lucas应助科研通管家采纳,获得30
22秒前
22秒前
圆锥香蕉应助科研通管家采纳,获得20
22秒前
科研通AI2S应助科研通管家采纳,获得10
22秒前
科研通AI2S应助科研通管家采纳,获得10
22秒前
科目三应助科研通管家采纳,获得10
22秒前
充电宝应助科研通管家采纳,获得10
22秒前
脑洞疼应助科研通管家采纳,获得10
22秒前
科研通AI5应助科研通管家采纳,获得10
22秒前
852应助科研通管家采纳,获得10
22秒前
科研通AI2S应助科研通管家采纳,获得10
22秒前
科研通AI2S应助科研通管家采纳,获得10
22秒前
情怀应助科研通管家采纳,获得10
23秒前
23秒前
感动黄豆发布了新的文献求助10
23秒前
26秒前
搞怪冷风完成签到,获得积分10
27秒前
lucky完成签到,获得积分10
27秒前
量子星尘发布了新的文献求助10
28秒前
30秒前
科目三应助战斗暴龙兽采纳,获得10
34秒前
34秒前
34秒前
35秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989115
求助须知:如何正确求助?哪些是违规求助? 3531367
关于积分的说明 11253688
捐赠科研通 3269986
什么是DOI,文献DOI怎么找? 1804868
邀请新用户注册赠送积分活动 882078
科研通“疑难数据库(出版商)”最低求助积分说明 809105